News Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Real-time Estimate Cboe BZX Other stock markets 10:37:40 2024-04-25 am EDT			5-day change	1st Jan Change
3.31 ^USD	+0.91%		-1.19%	+40.89%

Apr. 23	Lixte Biotechnology Files Up to $50 Million Mixed Shelf	MT
Mar. 27	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lixte Biotechnology Files Up to $50 Million Mixed Shelf	Apr. 23	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 27	MT
Top Midday Gainers	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	Mar. 27	AQ
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	Mar. 27	CI
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	Mar. 21	AQ
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	Mar. 21	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research	Feb. 27	AQ
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	Feb. 26	AQ
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	Feb. 26	CI
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial	Jan. 29	AQ
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	Jan. 29	CI
Top Premarket Decliners	Nov. 28	MT
Lixte Biotechnology : Investor Presentation - November 2023	Nov. 20	PU
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations	Nov. 13	AQ
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	23-10-18	CI
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	23-10-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Summary

Filters